This study is for people with metastatic non-small cell lung cancer (NSCLC), a type of lung cancer that has spread and cannot be removed by surgery. Researchers want to see if a combination of drugs called durvalumab and tremelimumab with chemotherapy is better than another drug, pembrolizumab, with chemotherapy. These drugs help the immune system fight cancer. To join, you must have specific genetic changes in your cancer, like STK11, KEAP1, or KRAS mutations.

• The study will last several months with visits every 3 to 4 weeks.
• You will receive treatments through an IV (a tube into your vein).
• Researchers will monitor your health and how well the treatment works.

You'll need to have regular check-ups, blood tests, and scans to see how the cancer is responding. Both you and your doctor will know which treatment you're getting. Safety and any side effects will be closely watched. If the treatment stops working or you choose to exit, you will stop receiving the study medication.